UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004325
Receipt number R000005166
Scientific Title The efficacy and safety of Yokukansan for BPSD in Alzheimer's disease. a randomized, double-blind, placebo-control trial.
Date of disclosure of the study information 2011/02/01
Last modified on 2013/04/09 05:15:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The efficacy and safety of Yokukansan for BPSD in Alzheimer's disease. a randomized, double-blind, placebo-control trial.

Acronym

The efficacy and safety of Yokukansan for BPSD in Alzheimer's disease.

Scientific Title

The efficacy and safety of Yokukansan for BPSD in Alzheimer's disease. a randomized, double-blind, placebo-control trial.

Scientific Title:Acronym

The efficacy and safety of Yokukansan for BPSD in Alzheimer's disease.

Region

Japan


Condition

Condition

Alzheimer's disease

Classification by specialty

Geriatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We investigate the superiority of Yokukansan over placebo on BPSD (Behavioral and Psychological Symptoms of Dementia) in Alzheimer's disease.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Neuropsychiatric Inventory-Q-J(NPI-Q-J)

Key secondary outcomes

Mini-Mental-State-Examination-J (MMSE-J)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

TSUMURA Yokukansan Extract Granules
(active drug)

Interventions/Control_2

TSUMURA Yokukansan Extract Granules
(placebo)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

55 years-old <=

Age-upper limit

84 years-old >=

Gender

Male and Female

Key inclusion criteria

1)Patients with mild to moderate Alzheimer's disease.
2)BPSD is present on NPI-Q-J.
3)Serum potassium level should be in normal range.
4)have a study partner able to provide an
independent evaluation of functioning.
5) Agreement to sign an informed consent

Key exclusion criteria

1)Patients with non-Alzheimer's dementia
2)No lesion exists in brain MRI.
3)Presence of severe illness
4)Those who have used Yokukansan ever before
5)Those who have joined any clinical trial
within 3 month
6)Those who are thought inadequate by their doctor.

Target sample size

140


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroyuki Arai

Organization

Institute of Development, Aging and Cancer
Tohoku university

Division name

Department of Geriatrics and Gerontology

Zip code


Address

4-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan

TEL

81-22-717-7182

Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Institute of Development, Aging and Cancer

Division name

Department of Geriatrics and Gerontology

Zip code


Address

4-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan

TEL

81-22-717-7182

Homepage URL


Email



Sponsor or person

Institute

Institute of Development, Aging and Cancer
Tohoku university, Department of Geriatrics and Gerontology

Institute

Department

Personal name



Funding Source

Organization

Ministory of health, labour and welfare

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

岩手医科大学病院(岩手県)
鳥取大学病院(鳥取県)
杏林大学病院(東京都)
慶應義塾大学病院(東京都)
群馬大学病院(群馬県)
山梨大学病院(山梨県)
大阪市立大学病院(大阪府)
けいめい記念病院(宮崎県)
東原整形外科病院(福岡県)
久里浜アルコール症センター(神奈川県)
仙台富沢病院(宮城県)
あおば脳神経外科(宮城県)
野村宏脳神経内科クリニック(宮城県)
など


Other administrative information

Date of disclosure of the study information

2011 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 10 Month 01 Day

Date of IRB


Anticipated trial start date

2011 Year 02 Month 01 Day

Last follow-up date

2013 Year 02 Month 05 Day

Date of closure to data entry

2013 Year 03 Month 27 Day

Date trial data considered complete

2013 Year 03 Month 27 Day

Date analysis concluded

2013 Year 06 Month 27 Day


Other

Other related information



Management information

Registered date

2010 Year 10 Month 05 Day

Last modified on

2013 Year 04 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005166


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name